| 8637646 |
Growth hormone variants |
James A. Wells |
2014-01-28 |
|
| 7090834 |
Vascular endothelial cell growth factor variants and uses thereof |
Abraham de Vos, Bing Li |
2006-08-15 |
$162,811,000 |
| 6936440 |
Selecting ligand agonists and antagonists |
James A. Wells |
2005-08-30 |
$258,929,000 |
| 6800740 |
Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications |
James A. Wells |
2004-10-05 |
$110,652,000 |
| 6780613 |
Growth hormone variants |
James A. Wells |
2004-08-24 |
$370,285,000 |
| 6525022 |
Receptor specific atrial natriuretic peptides |
David G. Lowe, David A. Oare, Robert McDowell, John Burnier |
2003-02-25 |
$187,752,000 |
| 6465235 |
Non-human carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors |
Richard R. Bott, Robert M. Caldwell, David A. Estell, Scott D. Power, James A. Wells |
2002-10-15 |
$4,514,000 |
| 6451561 |
Growth hormone variants |
James A. Wells |
2002-09-17 |
$60,675,000 |
| 6428954 |
Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
James A. Wells |
2002-08-06 |
$46,552,000 |
| 6376524 |
Triphenyl compounds as interleukin-4 antagonists |
Kenneth J. Barr, William Michael Flanagan, Wanli Lu, Brian Raimundo, Nathan D. Waal +3 more |
2002-04-23 |
|
| 6143523 |
Human growth hormone variants |
Henry B. Lowman, James A. Wells |
2000-11-07 |
$755,091,000 |
| 6136563 |
Human growth hormone variants comprising amino acid substitutions |
James A. Wells, Ross G. Clark, Kenneth C. Olson, Germaine Fuh |
2000-10-24 |
$168,095,000 |
| 6057292 |
Method for inhibiting growth hormone action |
Henry B. Lowman, James A. Wells, Ross G. Clark, Kenneth C. Olson, Germaine Fuh |
2000-05-02 |
$159,952,000 |
| 6057428 |
Variants of vascular endothelial cell growth factor |
Bruce Keyt, Francis Hung Nguyen, Napoleone Ferrara, James A. Wells, Bing Li |
2000-05-02 |
$159,952,000 |
| 6022711 |
Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1 |
Henry B. Lowman, James A. Wells |
2000-02-08 |
$154,077,000 |
| 6013478 |
Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
James A. Wells |
2000-01-11 |
$177,301,000 |
| 6004931 |
Method for inhibiting growth hormone action |
James A. Wells, Ross G. Clark, Kenneth C. Olson, Germaine Fuh |
1999-12-21 |
$119,948,000 |
| 5972682 |
Enzymatically active modified subtilisins |
Richard R. Bott, Robert M. Caldwell, David A. Estell, Scott D. Power, James A. Wells |
1999-10-26 |
|
| 5955340 |
Modified subtilisins having amino acid alterations |
Richard R. Bott, Robert M. Caldwell, David A. Estell, Scott D. Power, James A. Wells |
1999-09-21 |
|
| 5955346 |
Variants of human prolactin and human placeatal lactogen |
James A. Wells |
1999-09-21 |
$92,532,000 |
| 5854026 |
Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1 |
James A. Wells |
1998-12-29 |
$7,131,000 |
| 5849535 |
Human growth hormone variants |
Henry B. Lowman, James A. Wells, Ross G. Clark, Kenneth C. Olson, Germaine Fuh |
1998-12-15 |
$3,161,000 |
| 5846932 |
Receptor specific atrial natriuretic peptides |
David G. Lowe, David A. Oare, Robert McDowell, John Burnier |
1998-12-08 |
$9,313,000 |
| 5834250 |
Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
James A. Wells |
1998-11-10 |
$4,752,000 |
| 5801038 |
Modified subtilisins having amino acid alterations |
Richard R. Bott, Robert M. Caldwell, David A. Estell, Scott D. Power, James A. Wells |
1998-09-01 |
|
